title: Long-term results of half-fluence photodynamic therapy for chronic central serous chorioretinopathy.
abstract: OBJECTIVE
  To report long-term functional and anatomic results of safety-enhanced photodynamic therapy (PDT) with half-dose verteporfin for chronic central serous chorioretinopathy (CSC).
  
  
  METHODS
  A retrospective analysis of 29 eyes of 27 patients with chronic CSC was performed. All eyes received half-dose PDT. Visual acuity, central foveal thickness, and angiographic features were evaluated.
  
  
  RESULTS
  Mean follow-up time was 20 months (range 12-40). Mean best-corrected visual acuity improved from 0.45 ± 0.23 logMAR to 0.08 ± 0.08 logMAR. Twenty-five eyes (86%) had a complete resolution of the subretinal fluid after only one session and 4 eyes had recurrences, 3 of them at the same leaking area observed at baseline. At the end of the follow-up all eyes (100%) showed resolution of the subretinal fluid. There was no visual loss secondary to exaggerated response to the PDT, nor any other adverse events.
  
  
  CONCLUSIONS
  The long-term results of this study further support the safety and effectiveness of safety-enhanced PDT with half dose of verteporfin for the treatment of chronic CSC.
authors.affiliation: 2nd Department of Ophthalmology, University of Athens Medical School, Athens, Greece.
authors.forename: Alexandros
authors.initials: A
authors.lastname: Rouvas
authors.forename: Panagiotis
authors.initials: P
authors.lastname: Stavrakas
authors.forename: Panagiotis G
authors.initials: PG
authors.lastname: Theodossiadis
authors.forename: Polyxeni
authors.initials: P
authors.lastname: Stamatiou
authors.forename: Maria
authors.initials: M
authors.lastname: Milia
authors.forename: Emmanuela
authors.initials: E
authors.lastname: Giannakaki
authors.forename: Ioannis
authors.initials: I
authors.lastname: Datseris
mesh_terms: D000328:Adult; D056833:Central Serous Chorioretinopathy / Q000188:drug therapy* / Q000503:physiopathology; D002908:Chronic Disease; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D011166:Porphyrins / Q000008:administration & dosage* / Q000627:therapeutic use; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D000077362:Verteporfin; D014792:Visual Acuity / Q000502:physiology
chemical_list: D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin